Ziwig, finalist of the Short Eco Innovation Trophies

Over the next few weeks, we invite you to discover the 18 finalists of the 2022 Brief Eco Innovation Trophies. Today, focus on the Lyon-based start-up Ziwig, finalist in the health category, which developed Endotest®, the first endometriosis diagnostic saliva test.

In France, endometriosis affects 10% of women of childbearing age, ie 1.5 to 2.5 million women. This disease is characterized by the presence of fragments of a tissue similar to the endometrium (mucous membrane lining the inside of the uterus) outside the uterine cavity, at the level of various organs. At the time of menstruation, these tissue fragments react to hormonal stimulation and cause inflammation, which itself causes intense and debilitating pain and a wide variety of symptoms. The disease can also be completely asymptomatic. In this case, it is generally discovered by chance during a consultation motivated by difficulties in conceiving a child. Indeed, a significant proportion of patients with endometriosis also suffer from infertility.

Medical wandering

However, women with endometriosis mostly undergo a long medical wandering (8 to 12 years on average), during which they multiply appointments, analyzes and examinations before a diagnosis is made. Laparoscopy is still considered today as one of the reference examinations for the diagnosis of endometriosis. However, it is an invasive procedure that must be performed under general anesthesia.

The development of a non-invasive diagnostic test for endometriosis has therefore emerged as a major medical need. Ziwig, a start-up from Lyon bringing together doctors who are experts in endometriosis and engineers in artificial intelligence, has just developed a diagnostic test based on the sequencing of microRNAs present in saliva, validated by a clinical trial. ” This simple and non-invasive saliva test, called Endotest®, allows the early detection of all forms of endometriosis, even the most complex, with a reliability close to 100%. “says the company.

miRNA sequencing and artificial intelligence

The innovation is based on two breakthrough technologies, namely miRNA sequencing (NGS technology, New Generation Sequencing) and their analysis by bioinformatics using artificial intelligence. Ziwig’s association with an IGenSeq technology platform from the Paris Brain Institute has enabled the development of Endotest.

More generally, Ziwig intends to improve women’s health through a holistic approach and the development of innovative and effective diagnostic or prognostic tools.

Boehringer Ingelheim is a partner of the Short Eco Innovation Trophies

Partner of our event, Boehringer Ingelheim will present a trophy to one of the 18 finalists. The floor to Magali Hainaut, Global Innovation Animal Health Director at Boehringer Ingelheim.

We also thank all our partners who support this event and the innovative companies.

We want to say thanks to the writer of this article for this remarkable web content

Ziwig, finalist of the Short Eco Innovation Trophies

Visit our social media accounts as well as other pages related to themhttps://www.ai-magazine.com/related-pages/